MS4A1 and myeloid sarcoma: Indeed, real-world data from the Danish MS registry showed that the prevalence of low IgM and IgG levels among patients treated with CD20-depleting therapies (including rituximab, ocrelizumab, and ofatumumab) were 28 and 5%, respectively (1).